HWK-016, MUCIN-16-targeted ADC Clinical Trials (2026): 1 Studies for Endometrial Cancer & Platinum Resistant Ovarian Cancer

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

1 HWK-016, MUCIN-16-targeted ADC clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Endometrial Cancer & Platinum Resistant Ovarian Cancer) and 265 total planned enrollment. 1 HWK-016, MUCIN-16-targeted ADC clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07470853 (Feb 2028).

Where to Participate: All HWK-016, MUCIN-16-targeted ADC Trial Sites in the U.S. (3 sites across 3 states)

Every actively recruiting HWK-016, MUCIN-16-targeted ADCtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
CASTART - Los AngelesLos Angeles90025NCT07470853Map
NYStart - NyLake Success11042NCT07470853Map
UTSTART MountainSalt Lake City84119NCT07470853Map

HWK-016, MUCIN-16-targeted ADC clinical trials at a glance: phase × recruitment status

PhaserecruitingTotal
P111

Recruiting HWK-016, MUCIN-16-targeted ADC clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07470853A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.P1PROC265Mar 2026

All HWK-016, MUCIN-16-targeted ADC trials (1)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07470853A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.P1recruiting265Whitehawk Therapeutics, Inc.Mar 2026

HWK-016, MUCIN-16-targeted ADC clinical trials: frequently asked questions

How many HWK-016, MUCIN-16-targeted ADC clinical trials are there?
1 HWK-016, MUCIN-16-targeted ADC clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
Are HWK-016, MUCIN-16-targeted ADC clinical trials recruiting in 2026?
Yes — 1 HWK-016, MUCIN-16-targeted ADC trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
What conditions is HWK-016, MUCIN-16-targeted ADC being studied for?
HWK-016, MUCIN-16-targeted ADC is being studied for Endometrial Cancer, Platinum Resistant Ovarian Cancer, PROC. The trials are grouped by indication on this page.
What phase is HWK-016, MUCIN-16-targeted ADC in?
HWK-016, MUCIN-16-targeted ADC clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors HWK-016, MUCIN-16-targeted ADC clinical trials?
The lead sponsor across the most HWK-016, MUCIN-16-targeted ADC trials is Whitehawk Therapeutics, Inc.. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming HWK-016, MUCIN-16-targeted ADCas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai:

HWK-016, MUCIN-16-targeted ADC Clinical Trials (2026): 1 Studies | Hipa.ai